Considering that transient CDK4/6 inhibition can also activate this T‐cell population (Goel et al, 2017; Chaikovsky & Sage, 2018; Deng et al, 2018; Schaer et al, 2018), these effects could combine to enhance immune‐mediated tumour clearance. The gene discussed is CDK4; the disease is neoplasm.